You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Paediatric ODs in metabolic diseases: An Industry's perspective

Article type: Research Article

Authors: Camozzi, Carlos R.

Affiliations: Medical Affairs Department, Orphan Europe, Paris, France. E-mail: [email protected]

Abstract: To date, prescription of drugs which are unlicensed and/or unlabelled in the paediatric population is a concerning reality, particularly in the neonatal units (90%) and in the paediatric units (49%). Therefore, there is the need to develop effective and safe pharmacological treatments for the paediatric population in general.

Keywords: Paediatric population, clinical trial, orphan drug

DOI: 10.3233/PPL-2010-0287

Journal: Pharmaceuticals, Policy and Law, vol. 12, no. 1-2, pp. 139-141, 2010

Received 13 July 2010
|
Accepted 13 July 2010
|
Published: 2010
Price: EUR 27.50
Show more